World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
28965
World Ranking
13603
National Ranking
6911

Maria R. Baer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maria R. Baer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 643 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Maria R. Baer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maria R. Baer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Maria R. Baer is affiliated with the University of Maryland, Baltimore in the United States. Their research predominantly focuses on the field of Medicine, with significant contributions in Hematology, Genetics, Molecular Biology, Public Health, Environmental and Occupational Health, and Oncology.

Their work addresses several main topics including Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Multiple Myeloma Research and Treatments, and Histone Deacetylase Inhibitors Research.

Maria R. Baer has published extensively, with frequent contributions to well-known journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Blood Advances, and Cancer Research.

Several recent papers authored or co-authored by Maria R. Baer include:

  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study, 2021, The Lancet
  • KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results, 2021, Blood
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial, 2020, Nature Medicine
  • Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial, 2022, The Lancet Haematology
  • Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis, 2021, Journal of Clinical Oncology

Frequent co-authors collaborating with Maria R. Baer include:

  • Gary J. Schiller
  • Vu H. Duong
  • Eunice S. Wang
  • William Blum
  • Uma Borate

Best Publications

  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

    Alexander E. Perl;Giovanni Martinelli;Jorge E. Cortes;Andreas Neubauer

  • IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

    Guido Marcucci;Kati Maharry;Yue-Zhong Wu;Michael D. Radmacher

  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720

    Maria R. Baer;Stephen L. George;Richard K. Dodge;Kieran L. O'Loughlin

  • Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

    Krzysztof Mrózek;Guido Marcucci;Deedra Nicolet;Kati S. Maharry

  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

    Bijal D Shah;Armin Ghobadi;Olalekan O Oluwole;Aaron C Logan

  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

    Alexander E. Perl;Jessica K. Altman;Jorge Cortes;Catherine Smith

  • Signal transducer and activator of transcription proteins in leukemias.

    Mustafa Benekli;Maria R Baer;Heinz Baumann;Meir Wetzler

  • Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

    Karthika Natarajan;Yi Xie;Maria R. Baer;Maria R. Baer;Douglas D. Ross

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

    Heiko Becker;Guido Marcucci;Kati Maharry;Michael D. Radmacher

  • Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial

    David P. Steensma;Maria R. Baer;James L. Slack;Rena Buckstein

  • TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

    Klaus H. Metzeler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered

    John C. Byrd;Richard K. Dodge;Andrew Carroll;Maria R. Baer

  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

    Klaus H. Metzeler;Heiko Becker;Kati Maharry;Kati Maharry;Michael D. Radmacher;Michael D. Radmacher

  • Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia

    Guido Marcucci;Klaus H. Metzeler;Sebastian Schwind;Heiko Becker

  • RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

    Jason H. Mendler;Kati Maharry;Michael D. Radmacher;Krzysztof Mrózek

  • Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

    Peter Paschka;Guido Marcucci;Amy S. Ruppert;Susan P. Whitman

  • Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator

    Misbah Qadir;Kieran L. O'Loughlin;Stacy M. Fricke;Nicole A. Williamson

  • Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461.

    J C Byrd;R B Weiss;D C Arthur;D Lawrence

  • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

    Sherif S. Farag;Kellie J. Archer;Krzysztof Mrózek;Amy S. Ruppert

Frequent Co-Authors

Clara D. Bloomfield
Clara D. Bloomfield The Ohio State University
Richard A. Larson
Richard A. Larson University of Chicago
Guido Marcucci
Guido Marcucci City Of Hope National Medical Center
Bayard L. Powell
Bayard L. Powell Wake Forest University
Krzysztof Mrózek
Krzysztof Mrózek The Ohio State University
Michael A. Caligiuri
Michael A. Caligiuri City Of Hope National Medical Center
Richard Stone
Richard Stone Harvard University
Jonathan E. Kolitz
Jonathan E. Kolitz Hofstra University
Susan P. Whitman
Susan P. Whitman The Ohio State University
Mark J. Levis
Mark J. Levis Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers but seeking alternatives to traditional medical school, there are several flexible study options and in-demand roles to consider. Direct entry MSN online programs are an effective pathway for individuals with non-nursing backgrounds who wish to become advanced practice nurses quickly, often without first earning a BSN.

If you prefer a faster route into the field, ADN programs (Associate Degree in Nursing) offer streamlined training and may have less competitive admissions requirements compared to BSN programs.

Non-clinical roles are also a vital part of the healthcare system. The best medical billing and coding schools online provide training with financial aid options, preparing you for essential administrative positions supporting patient care.

Lastly, some nursing schools that don't require TEAS test offer alternative entry paths, reducing standardized test barriers and making nursing education even more accessible. Each of these pathways opens new opportunities in the dynamic field of healthcare.

Best Scientists Citing Maria R. Baer

Trending Scientists

Recently Published Articles